John Lesnick

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 228 citations

Medicine, Oncology, Pharmacology +16

Pharmacological pleiotropism of the human recombinant <i>α</i>_1A‐adrenoceptor: implications for <i>α</i>₁‐adrenoceptor classification

Anthony Ford, Donald V. Daniels, David J. Chang et al. · British Journal of Pharmacology · 1997 · 220 citations · Full text

Medicine, Biochemistry, Pharmacology +6

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Daniel P. Sutherlin, Linda Bao, Megan Berry et al. · Journal of Medicinal Chemistry · 2011 · 217 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.

Anthony Ford, Nicolas F. Arredondo, David R. Blue et al. · Molecular Pharmacology · 1996 · 193 citations

Medicine, Pharmacology, Urology +13

Ligand Efficacy and Potency at Recombinant α2 Adrenergic Receptors

Jeffrey R. Jasper, John Lesnick, Leon Chang et al. · Biochemical Pharmacology · 1998 · 156 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12